Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 13/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 11/20 | 0.46 |
| ▸ | CDC25B | P30305 | 11/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.45 |
| ▸ | PPARA | Q07869 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | PTPN6 | P29350 | 5/20 | 0.42 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246506 | 0.89 | PPARG (0.49) | PPARGPPARAMAOB | |
| SCHEMBL4250702 | 0.87 | PTPN1 (0.57) | PTPN1PTPN2CDC25BPPARGPPARA | |
| SCHEMBL4247957 | 0.87 | PTPN1 (0.57) | PTPN1PTPN2CDC25BPPARGPPARA | |
| SCHEMBL4247961 | 0.87 | PTPN1 (0.57) | PTPN1PTPN2CDC25BPPARGPPARA | |
| SCHEMBL4251665 | 0.81 | PPARG (0.51) | PPARGPPARAMAOBPARP10 | |
| SCHEMBL4246884 | 0.80 | PPARG (0.60) | PTPN1PPARGPPARAMAOBPARP15 | |
| SCHEMBL4243635 | 0.80 | PPARG (0.60) | PTPN1PPARGPPARAMAOBPARP15 | |
| SCHEMBL4243636 | 0.80 | PPARG (0.60) | PTPN1PPARGPPARAMAOBPARP15 | |
| SCHEMBL4246234 | 0.80 | PTPN1 (0.52) | PTPN1PTPN2CDC25BPPARGPPARA | |
| SCHEMBL4243352 | 0.75 | PPARA (0.61) | PPARGPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | claimed |
| US-20090012069-A1 | Novel Antidiabetic Compounds | CADILA HEALTHCARE LIMITED (IN) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012069-A1 | Novel Antidiabetic Compounds | GPR119, SLC5A1, SLC5A2 | PTPN1 724/4885PTPN2 852/4885CDC25B 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.